Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
180 Life Sciences's Business Segments
180 Life Sciences's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
5
Largest Segment
Aircraft Engine Rental Revenue
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Aircraft Engine Rental Revenue0%
- Aircraft Engine Rental0%
- Staking Revenue0%
- Native Staking Revenue0%
- Liquid Staking Revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Aircraft Engine Rental Revenue | $ 2 | - |
| Aircraft Engine Rental | $ 2 | - |
| Staking Revenue | - | 0% |
2 more segments available
Sign in to unlock the full 180 Life Sciences dataset.
Revenue by Product & Service Category - FY
- Aircraft Engine Rental100%
- Aircraft Engine Rental Revenue100%
- Staking Revenue0%
- Native Staking Revenue0%
- Liquid Staking Revenue0%
Revenue by Product & Service Category - FY
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Aircraft Engine Rental | $ 1 | 100% |
| Aircraft Engine Rental Revenue | $ 1 | 100% |
| Staking Revenue | - | 0% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
2 more categories available
Sign in to unlock the full 180 Life Sciences dataset.
Annual Results
Revenue Share by Reportable Segment - FY
- Aircraft Engine Rental Revenue0%
- Aircraft Engine Rental0%
- Staking Revenue0%
- Native Staking Revenue0%
- Liquid Staking Revenue0%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Aircraft Engine Rental Revenue | $ 2 | - |
| Aircraft Engine Rental | $ 2 | - |
| Staking Revenue | - | 0% |
2 more segments available
Sign in to unlock the full 180 Life Sciences dataset.
Description of 180 Life Sciences
180 Life Sciences Corp is a clinical-stage biotechnology company dedicated to developing and commercializing novel therapies for inflammatory diseases, fibrosis, and aging-related diseases. Headquartered in Montclair, New Jersey, the company was founded in 2020 and is publicly traded on the NASDAQ under the ticker symbol ATNF.
The primary focus of 180 Life Sciences is centered around addressing the underlying causes of chronic inflammation, a critical factor in the development and progression of various diseases. The company aims to deliver transformative treatments that can significantly improve patients' lives and alleviate the burden of these debilitating conditions.
One of the key areas of research for 180 Life Sciences involves investigating the potential of using cannabis-based therapies to treat inflammatory bowel disease (IBD). The company is developing a targeted therapy called AP-003, which is a cannabidiol derivative for treating IBD. This product aims to reduce inflammation in the gut while avoiding the psychoactive effects associated with traditional cannabis-based treatments.
Another significant focus of 180 Life Sciences is in fibrosis-related conditions, such as liver fibrosis and non-alcoholic steatohepatitis (NASH). Fibrosis occurs when excessive scarring and tissue thickening in organs impair their function. The company is actively working on developing a therapy called AP-014, which combines anti-TNF (tumor necrosis factor) antibodies with antifibrotic agents to treat fibrosis. This therapy is intended to halt or reverse the progression of fibrotic diseases, improving patients' quality of life.
Furthermore, 180 Life Sciences recognizes the association between aging and increased susceptibility to various diseases. As part of their focus on aging-related diseases, the company recently acquired the rights to a patented technology known as Synavive®. Synavive® is a glucocorticoid receptor agonist that has shown potential in reducing inflammation, pain, and other symptoms associated with arthritis. 180 Life Sciences aims to leverage this technology to develop a novel therapy for joint pain and inflammation.
In addition to their research and development efforts, 180 Life Sciences has a strong commitment to collaboration and partnerships. The company collaborates with leading academic institutions, healthcare professionals, and research organizations to advance their scientific understanding, develop innovative therapies, and bring them to market efficiently.
Overall, 180 Life Sciences Corp is dedicated to advancing the field of biotechnology and improving patient outcomes by developing novel therapies for inflammatory diseases, fibrosis, and aging-related conditions. With their strong focus on research, development, and strategic partnerships, the company aims to make a significant impact on the lives of millions of people worldwide.
The primary focus of 180 Life Sciences is centered around addressing the underlying causes of chronic inflammation, a critical factor in the development and progression of various diseases. The company aims to deliver transformative treatments that can significantly improve patients' lives and alleviate the burden of these debilitating conditions.
One of the key areas of research for 180 Life Sciences involves investigating the potential of using cannabis-based therapies to treat inflammatory bowel disease (IBD). The company is developing a targeted therapy called AP-003, which is a cannabidiol derivative for treating IBD. This product aims to reduce inflammation in the gut while avoiding the psychoactive effects associated with traditional cannabis-based treatments.
Another significant focus of 180 Life Sciences is in fibrosis-related conditions, such as liver fibrosis and non-alcoholic steatohepatitis (NASH). Fibrosis occurs when excessive scarring and tissue thickening in organs impair their function. The company is actively working on developing a therapy called AP-014, which combines anti-TNF (tumor necrosis factor) antibodies with antifibrotic agents to treat fibrosis. This therapy is intended to halt or reverse the progression of fibrotic diseases, improving patients' quality of life.
Furthermore, 180 Life Sciences recognizes the association between aging and increased susceptibility to various diseases. As part of their focus on aging-related diseases, the company recently acquired the rights to a patented technology known as Synavive®. Synavive® is a glucocorticoid receptor agonist that has shown potential in reducing inflammation, pain, and other symptoms associated with arthritis. 180 Life Sciences aims to leverage this technology to develop a novel therapy for joint pain and inflammation.
In addition to their research and development efforts, 180 Life Sciences has a strong commitment to collaboration and partnerships. The company collaborates with leading academic institutions, healthcare professionals, and research organizations to advance their scientific understanding, develop innovative therapies, and bring them to market efficiently.
Overall, 180 Life Sciences Corp is dedicated to advancing the field of biotechnology and improving patient outcomes by developing novel therapies for inflammatory diseases, fibrosis, and aging-related conditions. With their strong focus on research, development, and strategic partnerships, the company aims to make a significant impact on the lives of millions of people worldwide.
180 Life Sciences Corp is a biotechnology company focused on developing and commercializing innovative therapies for various health conditions. The company is particularly interested in advancing the understanding of and treatments for complex diseases through a multi-faceted approach that includes the following key segments, products, and services:
1. Research and Development (R&D)
180 Life Sciences invests heavily in R&D to discover and refine new therapeutic approaches, particularly in the areas of pain management, inflammation, and neurodegenerative diseases. The company leverages advanced technologies and scientific methodologies to explore novel treatment pathways.
a. Clinical Trials:
The company conducts extensive clinical trials to assess the safety and efficacy of its drug candidates. These trials are designed in phases, starting from small, early-stage trials to larger, later-stage studies that validate the treatment in larger populations.
b. Pre-clinical Studies:
Before clinical trials, 180 Life Sciences carries out preclinical research, which involves laboratory experiments and animal studies to gauge the biological activity and mechanism of action of its therapeutic candidates.
Therapeutics Development
180 Life Sciences is primarily focused on developing therapies in specific therapeutic areas, including:
a. Pain Management:
The company is exploring treatments for chronic pain conditions such as arthritis and neuropathic pain. Their products aim to provide effective pain relief with fewer side effects compared to traditional pain medications.
b. Inflammatory Diseases:
They also target inflammatory conditions, recognizing the importance of inflammation in various diseases including autoimmune disorders. Their therapeutic candidates are designed to modulate inflammatory responses.
c. Neurodegenerative Disorders:
180 Life Sciences is developing therapies for neurodegenerative diseases such as Parkinson’s disease. The goal is to create treatments that slow disease progression and improve patient quality of life.
Partnerships and Collaborations
To enhance its development capabilities, 180 Life Sciences engages in strategic partnerships and collaborations with academic institutions, research organizations, and other companies. Through these collaborations, the company can leverage external expertise, share research costs, and accelerate the development of its products.
Manufacturing and Supply Chain
a. Production Capabilities:
180 Life Sciences works closely with manufacturing partners to ensure that its products are produced under stringent quality standards. The manufacturing process is designed to scale with demand while maintaining compliance with regulatory requirements.
b. Logistics and Distribution:
The company develops efficient logistics and distribution strategies to ensure that its products reach healthcare providers and patients in a timely manner.
Regulatory Affairs
Navigating the regulatory landscape is crucial for the success of biotechnology companies. 180 Life Sciences employs a dedicated regulatory affairs team that ensures all products meet the necessary legal and regulatory requirements. This includes preparing documentation for regulatory submissions and maintaining compliance throughout the product lifecycle.
Intellectual Property Management
To protect its innovations, 180 Life Sciences actively manages its intellectual property portfolio. This involves filing patents for new discoveries, trade secrets, and other proprietary technologies that provide competitive advantages in the marketplace.
Commercialization Strategies
Once products have successfully completed clinical trials and received regulatory approvals, 180 Life Sciences will implement commercialization strategies. This may include:
a. Marketing and Sales:
The company develops marketing strategies to promote its products within the medical community, ensuring they reach the intended healthcare providers and patients.
b. Education and Training:
Educational initiatives are crucial for ensuring that healthcare professionals understand the benefits and proper use of the company’s therapies. 180 Life Sciences may offer training and resources to facilitate this.
c. Patient Access Programs:
These programs are designed to improve patient access to therapies, particularly for those in underserved communities or with financial constraints.
8. Patient-Centric Services
The company emphasizes a patient-centric approach by incorporating patient feedback into product development and improving patient outcomes. This may include:
a. Support Programs:
180 Life Sciences may offer support services for patients, including counseling and informational resources about managing their conditions and treatment.
b. Surveys and Feedback Tools:
Gathering patient feedback on treatment experiences helps the company refine its offerings and address any unmet needs in the patient community.
Conclusion
180 Life Sciences Corp aims to transform the landscape of therapy development through its comprehensive suite of segments, products, and services. Their focus on research and development, coupled with an understanding of patient needs and regulatory complexities, positions them to make significant contributions to the field of biotechnology and healthcare.
1. Research and Development (R&D)
180 Life Sciences invests heavily in R&D to discover and refine new therapeutic approaches, particularly in the areas of pain management, inflammation, and neurodegenerative diseases. The company leverages advanced technologies and scientific methodologies to explore novel treatment pathways.
a. Clinical Trials:
The company conducts extensive clinical trials to assess the safety and efficacy of its drug candidates. These trials are designed in phases, starting from small, early-stage trials to larger, later-stage studies that validate the treatment in larger populations.
b. Pre-clinical Studies:
Before clinical trials, 180 Life Sciences carries out preclinical research, which involves laboratory experiments and animal studies to gauge the biological activity and mechanism of action of its therapeutic candidates.
Therapeutics Development
180 Life Sciences is primarily focused on developing therapies in specific therapeutic areas, including:
a. Pain Management:
The company is exploring treatments for chronic pain conditions such as arthritis and neuropathic pain. Their products aim to provide effective pain relief with fewer side effects compared to traditional pain medications.
b. Inflammatory Diseases:
They also target inflammatory conditions, recognizing the importance of inflammation in various diseases including autoimmune disorders. Their therapeutic candidates are designed to modulate inflammatory responses.
c. Neurodegenerative Disorders:
180 Life Sciences is developing therapies for neurodegenerative diseases such as Parkinson’s disease. The goal is to create treatments that slow disease progression and improve patient quality of life.
Partnerships and Collaborations
To enhance its development capabilities, 180 Life Sciences engages in strategic partnerships and collaborations with academic institutions, research organizations, and other companies. Through these collaborations, the company can leverage external expertise, share research costs, and accelerate the development of its products.
Manufacturing and Supply Chain
a. Production Capabilities:
180 Life Sciences works closely with manufacturing partners to ensure that its products are produced under stringent quality standards. The manufacturing process is designed to scale with demand while maintaining compliance with regulatory requirements.
b. Logistics and Distribution:
The company develops efficient logistics and distribution strategies to ensure that its products reach healthcare providers and patients in a timely manner.
Regulatory Affairs
Navigating the regulatory landscape is crucial for the success of biotechnology companies. 180 Life Sciences employs a dedicated regulatory affairs team that ensures all products meet the necessary legal and regulatory requirements. This includes preparing documentation for regulatory submissions and maintaining compliance throughout the product lifecycle.
Intellectual Property Management
To protect its innovations, 180 Life Sciences actively manages its intellectual property portfolio. This involves filing patents for new discoveries, trade secrets, and other proprietary technologies that provide competitive advantages in the marketplace.
Commercialization Strategies
Once products have successfully completed clinical trials and received regulatory approvals, 180 Life Sciences will implement commercialization strategies. This may include:
a. Marketing and Sales:
The company develops marketing strategies to promote its products within the medical community, ensuring they reach the intended healthcare providers and patients.
b. Education and Training:
Educational initiatives are crucial for ensuring that healthcare professionals understand the benefits and proper use of the company’s therapies. 180 Life Sciences may offer training and resources to facilitate this.
c. Patient Access Programs:
These programs are designed to improve patient access to therapies, particularly for those in underserved communities or with financial constraints.
8. Patient-Centric Services
The company emphasizes a patient-centric approach by incorporating patient feedback into product development and improving patient outcomes. This may include:
a. Support Programs:
180 Life Sciences may offer support services for patients, including counseling and informational resources about managing their conditions and treatment.
b. Surveys and Feedback Tools:
Gathering patient feedback on treatment experiences helps the company refine its offerings and address any unmet needs in the patient community.
Conclusion
180 Life Sciences Corp aims to transform the landscape of therapy development through its comprehensive suite of segments, products, and services. Their focus on research and development, coupled with an understanding of patient needs and regulatory complexities, positions them to make significant contributions to the field of biotechnology and healthcare.